Wordt geladen...
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
Venetoclax has been approved by the United States Food and Drug Administration since 2016 as a monotherapy for treating patients with relapsed/refractory chronic lymphocytic leukemia having 17p deletion. It has led to a breakthrough in the treatment of hematologic malignancies in recent years. Howev...
Bewaard in:
| Gepubliceerd in: | Cancer Cell Int |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7597043/ https://ncbi.nlm.nih.gov/pubmed/33292251 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-020-01614-z |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|